Retatrutide: the triple agonist, explained.
The newest GLP-1-class drug just posted the highest weight loss the field has seen, up to 30%. Here is what it is, how it compares, and what it means for women. Every claim cites its source.
Retatrutide is a triple agonist, it activates three gut-hormone receptors (GIP, GLP-1 and glucagon) where semaglutide activates one and tirzepatide two. The added glucagon receptor appears to do something its predecessors cannot: rather than only reducing how much you eat, it increases how much energy you burn. That combination is the leading explanation for its record trial numbers.
In the Phase 3 TRIUMPH-1 trial reported in May 2026, the highest dose produced an average of 28.3% body-weight loss at 80 weeks, rising to about 30.3% at 104 weeks for participants who started heavier and stayed on the drug. For comparison: semaglutide (Wegovy) averages around 15%, tirzepatide (Zepbound) around 21%.
One fact frames everything else: retatrutide is investigational and not available. It is in Phase 3 trials, with a possible approval years away. The drug your prescriber can offer today is still semaglutide or tirzepatide, and how you use it is what decides your results this year. The deeper the weight loss any of these drugs delivers, the more it matters what kind of weight leaves: a quarter to a third of it is muscle, unless you take deliberate steps to keep it.
Four things worth understanding.
Three receptors, not one
Retatrutide acts on GIP, GLP-1 and glucagon. Semaglutide acts on one; tirzepatide on two. The glucagon leg appears to raise energy expenditure, eating less and burning more.
The biggest number the field has seen
TRIUMPH-1 (May 2026): up to 28.3% average weight loss at 80 weeks, ~30.3% at 104 weeks for higher-weight continuers. Semaglutide averages ~15%; tirzepatide ~21%.
Bigger loss, bigger muscle stakes
Roughly a quarter to a third of weight lost is lean mass without deliberate steps. Thirty percent of a larger number is more muscle on the line, sharper for women, who start with less.
What you can do now
Retatrutide is years away. The protection isn't: enough protein and resistance training cut muscle loss 50–95%. Build that foundation on the GLP-1 you already take.
Read deeper, every claim cited.
Evidence-based summaries, each citing its primary source. Start with the three retatrutide explainers, then the muscle science that makes them matter.
Retatrutide, explained: the triple agonist behind 30% weight loss
Lilly's TRIUMPH-1 trial just reported the highest weight loss the field has seen, up to 30% of body weight. Here is what retatrutide actually is, what the numbers mean, and the…
Retatrutide vs tirzepatide vs semaglutide: how to think about the triple agonist
One receptor, two, or three. The numbers climb with each. But the drug that wins on a trial chart is not always the one that's right for you, and the newest one isn't available…
What 30% weight loss means for women: retatrutide, muscle, and the higher stakes
The biggest weight-loss number the field has seen is also the biggest test of a quiet truth: the more you lose, the more muscle is on the line. For women, with less muscle to…
Muscle on a GLP-1: the 2-hour-a-week rule that changes everything
Protein alone slows muscle loss. Protein plus two short resistance sessions a week preserves it. The evidence, and a practical starting plan.
Why 120 grams of protein matters when you can barely eat breakfast
A third of the weight lost on a GLP-1 can be muscle. Here's what the research says about protecting lean mass when appetite disappears.
Mounjaro vs Wegovy: how to think about the choice
Tirzepatide loses more weight on average. Semaglutide has more years of safety data. The right answer is rarely about averages, here's the framework your prescriber is probably…
What people ask about retatrutide.
Is retatrutide FDA approved?
When will retatrutide be available?
Is retatrutide better than Mounjaro or tirzepatide?
Does retatrutide cause muscle loss?
Is retatrutide safe for women?
The next drug is years away. The foundation isn’t.
Steady tracks the GLP-1s you can take today, Ozempic, Wegovy, Mounjaro, Zepbound, and is built around the muscle, protein, cycle and symptom data that protect what matters while you lose. Free on the App Store. iPhone only, for now.
